# A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients

> **NCT00002122** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 720 (—)

## Conditions studied

- Mycoses
- Mycobacterium Avium-Intracellulare Infection
- HIV Infections

## Interventions

- **DRUG:** Azithromycin
- **DRUG:** Rifabutin
- **DRUG:** Fluconazole

## Key facts

- **NCT ID:** NCT00002122
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 720 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002122, "A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00002122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*